Search research articles
Contact Us
Filters
Showing results (151-160 of 268) with videos related to
Page
of 27
Sort By:
Human Pathology
|
April 5, 2019
The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement
Snjezana Dogan, Charlotte K Y Ng, Bin Xu, et al.
The Oncologist
|
May 10, 2022
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers
Xiuning Le, Christina Baik, Jessica Bauman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2022
Selpercatinib in Patients With <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
Alexander Drilon, Vivek Subbiah, Oliver Gautschi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 30, 2023
Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers
Julia Rotow, Jyoti D Patel, Matthew P Hanley, et al.
The Oncologist
|
June 16, 2021
A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors
Hui K Gan, Michael Millward, Mathilde Jalving, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 28, 2019
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden
Ryma Benayed, Michael Offin, Kerry Mullaney, et al.
The Oncologist
|
August 28, 2020
Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series
Jacques Cadranel, Stephen V Liu, Michaël Duruisseaux, et al.
Nature Communications
|
November 23, 2022
Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies
Yonina R Murciano-Goroff, Alison M Schram, Ezra Y Rosen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 5, 2022
Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy
Or Kalchiem-Dekel, Christina J Falcon, Christine M Bestvina, et al.
JCO Precision Oncology
|
April 9, 2019
Acquired <i>ALK</i> and <i>RET</i> Gene Fusions as Mechanisms of Resistance to Osimertinib in <i>EGFR</i>-Mutant Lung Cancers
Michael Offin, Romel Somwar, Natasha Rekhtman, et al.
Page
of 27
Search research articles
Search
Showing results (151-160 of 268) with videos related to
Sort By:
Page
of 27
Human Pathology
|
April 5, 2019
The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement
Snjezana Dogan, Charlotte K Y Ng, Bin Xu, et al.
The Oncologist
|
May 10, 2022
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers
Xiuning Le, Christina Baik, Jessica Bauman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2022
Selpercatinib in Patients With <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
Alexander Drilon, Vivek Subbiah, Oliver Gautschi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 30, 2023
Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers
Julia Rotow, Jyoti D Patel, Matthew P Hanley, et al.
The Oncologist
|
June 16, 2021
A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors
Hui K Gan, Michael Millward, Mathilde Jalving, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 28, 2019
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden
Ryma Benayed, Michael Offin, Kerry Mullaney, et al.
The Oncologist
|
August 28, 2020
Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series
Jacques Cadranel, Stephen V Liu, Michaël Duruisseaux, et al.
Nature Communications
|
November 23, 2022
Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies
Yonina R Murciano-Goroff, Alison M Schram, Ezra Y Rosen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 5, 2022
Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy
Or Kalchiem-Dekel, Christina J Falcon, Christine M Bestvina, et al.
JCO Precision Oncology
|
April 9, 2019
Acquired <i>ALK</i> and <i>RET</i> Gene Fusions as Mechanisms of Resistance to Osimertinib in <i>EGFR</i>-Mutant Lung Cancers
Michael Offin, Romel Somwar, Natasha Rekhtman, et al.
Page
of 27